Latest Oncosec Medical Inc (ONCS) Headlines O
Post# of 121
Posted On: 03/10/2014 9:51:34 PM
Latest Oncosec Medical Inc (ONCS) Headlines
OncoSec Medical to Present at 24th Annual Wall Street Analyst Forum Institutional Investor Conference
Business Wire - Tue Feb 25, 5:02AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, today announced that Punit Dhillon, President and CEO, will present a corporate overview of the company at the 24th Annual Wall Street Analyst Forum Institutional Investor Conference at the University Club in New York, New York on Monday, March 3rd at 12:05 p.m. (EST).
OTC Daily Alert Stock Watch - OncoSec Medical Incorporated (OTCQB: ONCS)
WorldStockWire - Thu Feb 06, 2:45PM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
OncoSec Medical to Present at 16th Annual BIO CEO & Investor Conference
Business Wire - Tue Feb 04, 5:02AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, today announced that Punit Dhillon, President and CEO, will present a corporate overview of the company at the 16th Annual BIO CEO & Investor Conference at the Waldorf Astoria in New York, New York on Monday, February 10 at 4:00 p.m. (EST) in the third floor Basildon Suite.
State of Tech: A Guide to the Q4 2013 Earnings Season that Boldly Predicts the Winners and Losers, Including Covering Teradyne, Sanmina, and Many More
PR Newswire - Fri Jan 17, 7:37AM CST
Next Inning Technology Research (http://www.nextinning.com), an online investment newsletter focused on technology stocks, has issued updated outlooks for Teradyne (NYSE: TER), Sanmina (Nasdaq: SANM), Lattice Semiconductor (Nasdaq: LSCC), Skyworks Solutions (Nasdaq: SWKS) and Towerstream (Nasdaq: TWER).
Princess Cruises Launches Its Most Extensive Marketing Campaign Ever, Inviting Travelers Desiring Meaningful Vacations to "Come Back New"
PR Newswire - Wed Jan 15, 7:00AM CST
As the new year begins, Princess Cruises is launching a fresh advertising campaign to remind travelers that cruising can transform and enrich their lives, and set the line's cruise vacations apart as an opportunity for passengers to "come back new." The $20 million program will be the company's most extensive ever, and marks a return to television and radio advertising for the brand, which has not taken to the airwaves for more than a decade.
OncoSec Medical Announces 2014 Strategic Update
Business Wire - Tue Jan 14, 5:02AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, today announced a strategic update and reported on progress made in 2013. Progress included advancing metastatic melanoma, Merkel cell clinical programs and preclinical combination studies with anti-PD-1, anti-PDL-1, and anti-CTLA4, which highlight a commercial path forward.
OncoSec Medical to Present at "TEN"; Noble Financial Capital Markets' Tenth Annual Equity Conference
Business Wire - Mon Jan 13, 5:03AM CST
OncoSec Medical Inc. (OTCQB:ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, today announced that Punit Dhillon, President and CEO, will present at "TEN"; Noble Financial Capital Markets' Tenth Annual Equity Conference, at Club Med in Sandpiper Bay, Florida, on Tuesday, January 21 at 1:30 p.m. (EST) in Room 1.
Sezary Syndrome Global Clinical Trials Review, H2 2013 - Features Players such as Merck & Co., Inc. and Shionogi & Co., Ltd.
M2 - Fri Jan 10, 3:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/l3xgrw/sezary_syndrome) has announced the addition of the "Sezary Syndrome Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Sezary Syndrome Global Clinical Trials Review, H2, 2013" provides data on the Sezary Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Sezary Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Sezary Syndrome. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies Mentioned: -Angimmune LLC -Eisai Co., Ltd. -Emergent BioSolutions Inc. -Janssen Global Services, LLC -Kirin Holdings Company, Limited -Merck & Co., Inc. -National Cancer Institute -Northwestern University -OncoSec Medical Inc. -Roswell Park Cancer Institute -Shionogi & Co., Ltd. -Spectrum Pharmaceuticals, Inc. -Stanford University -University of Washington -Wake Forest University For more information visit http://www.researchandmarkets.com/research/l3...y_syndrome About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
OncoSec Medical to Present Corporate Update at Biotech Showcase 2014
Business Wire - Tue Jan 07, 5:03AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a biotechnology company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, today announced that Punit Dhillon, President and CEO, will provide a corporate update at Biotech Showcase 2014; one of the world's largest life sciences conferences held annually in San Francisco.
OncoSec Medical Announces Positive Interim Data from Phase 2 Study of OMS-I100 in Metastatic Melanoma
Business Wire - Mon Dec 16, 5:02AM CST
OncoSec Medical Inc. (OTCQB:ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, today announced positive interim data from its ongoing Phase 2 trial of OMS-I100 in the treatment of metastatic melanoma. The results were presented by principal investigator Adil Daud, MD, at the Advances in Cancer Immunotherapy meeting at the University of California San Francisco.
OncoSec Medical Announces Hire of Chief Medical Officer
Business Wire - Thu Dec 12, 5:05AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, announced today that Dr. Robert H. Pierce has joined the company as Chief Medical Officer.
OncoSec Medical to Present at the 6th Annual LD Micro Conference
Business Wire - Tue Nov 26, 5:07AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, has announced it will be presenting at the Sixth Annual LD Micro Conference.
Exclusive Stock Reports on HIPP, QUAN and ONCS
ACCESSWIRE - Fri Nov 08, 12:32AM CST
Hipcricket Inc (OTC:HIPP), Quantum Internatinal Corp (OTC:QUAN) and OncoSec Medical Inc (OTC:ONCS) have been added to our watch list.
New In Depth Equity Reports on ONCS, DROP and MSLP
ACCESSWIRE - Mon Oct 28, 12:16AM CDT
OncoSec Medical Inc. (PINK: ONCS), Fuse Science, Inc. (OTC: DROP), and MusclePharm Corporation (OTC: MSLP) have been added to our watch list.
OncoSec President and CEO Publishes New Blog Entitled "PD-1 and OncoSec's Combination Study"
ACCESSWIRE - Mon Oct 21, 8:43AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), published a new blog post on The Chairman's Blog, written by the company's President and CEO, Punit Dhillon. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
OncoSec Medical Announces Positive Preliminary Safety Data in Combination Study
Business Wire - Tue Oct 08, 5:05AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, has announced positive preliminary animal data demonstrating the benefits of combining the company's ImmunoPulse with anti-CTLA4 and anti-PD1 antibodies.
OncoSec Medical to Present at the 2013 Aegis Capital Healthcare Conference
Business Wire - Fri Sep 20, 5:05AM CDT
OncoSec Medical Inc. (OTCQB:ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, has announced it will be presenting at the 2013 Aegis Capital Healthcare Conference. The presentation will take place at 9:45am PT on Thursday, September 26 at The Encore at Wynn in Las Vegas, NV.
OncoSec Medical Closes $12 Million Public Offering
Business Wire - Thu Sep 19, 5:05AM CDT
OncoSec Medical Inc. (OTCQB:ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, today announced that it has closed a registered public offering of 47,792,000 shares of its common stock at $0.25 per share and warrants to purchase up to 23,896,000 shares of common stock at an exercise price of $0.35 per share for four years.
OncoSec Medical Inc reports launch of USD12m public offering
M2 - Tue Sep 17, 6:58AM CDT
Biopharmaceutical company OncoSec Medical Inc (Other OTC:ONCS) announced on Monday the execution of definitive agreements to sell USD12m of securities in a registered public offering.
OncoSec Medical Announces $12 Million Public Offering
Business Wire - Mon Sep 16, 5:05AM CDT
OncoSec Medical Inc. (OTCQB:ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, announced today that it has entered into definitive agreements with institutional investors to purchase approximately $12 million of securities in a registered public offering. OncoSec has agreed to sell to institutional investors an aggregate of 47,792,000 shares of its common stock at $0.25 per share. Additionally, investors will receive warrants to purchase up to 23,896,000 shares of common stock at an exercise price of $0.35 per share for a term of four years.
OncoSec Medical to Present at 24th Annual Wall Street Analyst Forum Institutional Investor Conference
Business Wire - Tue Feb 25, 5:02AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, today announced that Punit Dhillon, President and CEO, will present a corporate overview of the company at the 24th Annual Wall Street Analyst Forum Institutional Investor Conference at the University Club in New York, New York on Monday, March 3rd at 12:05 p.m. (EST).
OTC Daily Alert Stock Watch - OncoSec Medical Incorporated (OTCQB: ONCS)
WorldStockWire - Thu Feb 06, 2:45PM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
OncoSec Medical to Present at 16th Annual BIO CEO & Investor Conference
Business Wire - Tue Feb 04, 5:02AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, today announced that Punit Dhillon, President and CEO, will present a corporate overview of the company at the 16th Annual BIO CEO & Investor Conference at the Waldorf Astoria in New York, New York on Monday, February 10 at 4:00 p.m. (EST) in the third floor Basildon Suite.
State of Tech: A Guide to the Q4 2013 Earnings Season that Boldly Predicts the Winners and Losers, Including Covering Teradyne, Sanmina, and Many More
PR Newswire - Fri Jan 17, 7:37AM CST
Next Inning Technology Research (http://www.nextinning.com), an online investment newsletter focused on technology stocks, has issued updated outlooks for Teradyne (NYSE: TER), Sanmina (Nasdaq: SANM), Lattice Semiconductor (Nasdaq: LSCC), Skyworks Solutions (Nasdaq: SWKS) and Towerstream (Nasdaq: TWER).
Princess Cruises Launches Its Most Extensive Marketing Campaign Ever, Inviting Travelers Desiring Meaningful Vacations to "Come Back New"
PR Newswire - Wed Jan 15, 7:00AM CST
As the new year begins, Princess Cruises is launching a fresh advertising campaign to remind travelers that cruising can transform and enrich their lives, and set the line's cruise vacations apart as an opportunity for passengers to "come back new." The $20 million program will be the company's most extensive ever, and marks a return to television and radio advertising for the brand, which has not taken to the airwaves for more than a decade.
OncoSec Medical Announces 2014 Strategic Update
Business Wire - Tue Jan 14, 5:02AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, today announced a strategic update and reported on progress made in 2013. Progress included advancing metastatic melanoma, Merkel cell clinical programs and preclinical combination studies with anti-PD-1, anti-PDL-1, and anti-CTLA4, which highlight a commercial path forward.
OncoSec Medical to Present at "TEN"; Noble Financial Capital Markets' Tenth Annual Equity Conference
Business Wire - Mon Jan 13, 5:03AM CST
OncoSec Medical Inc. (OTCQB:ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, today announced that Punit Dhillon, President and CEO, will present at "TEN"; Noble Financial Capital Markets' Tenth Annual Equity Conference, at Club Med in Sandpiper Bay, Florida, on Tuesday, January 21 at 1:30 p.m. (EST) in Room 1.
Sezary Syndrome Global Clinical Trials Review, H2 2013 - Features Players such as Merck & Co., Inc. and Shionogi & Co., Ltd.
M2 - Fri Jan 10, 3:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/l3xgrw/sezary_syndrome) has announced the addition of the "Sezary Syndrome Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Sezary Syndrome Global Clinical Trials Review, H2, 2013" provides data on the Sezary Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Sezary Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Sezary Syndrome. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies Mentioned: -Angimmune LLC -Eisai Co., Ltd. -Emergent BioSolutions Inc. -Janssen Global Services, LLC -Kirin Holdings Company, Limited -Merck & Co., Inc. -National Cancer Institute -Northwestern University -OncoSec Medical Inc. -Roswell Park Cancer Institute -Shionogi & Co., Ltd. -Spectrum Pharmaceuticals, Inc. -Stanford University -University of Washington -Wake Forest University For more information visit http://www.researchandmarkets.com/research/l3...y_syndrome About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
OncoSec Medical to Present Corporate Update at Biotech Showcase 2014
Business Wire - Tue Jan 07, 5:03AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a biotechnology company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, today announced that Punit Dhillon, President and CEO, will provide a corporate update at Biotech Showcase 2014; one of the world's largest life sciences conferences held annually in San Francisco.
OncoSec Medical Announces Positive Interim Data from Phase 2 Study of OMS-I100 in Metastatic Melanoma
Business Wire - Mon Dec 16, 5:02AM CST
OncoSec Medical Inc. (OTCQB:ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, today announced positive interim data from its ongoing Phase 2 trial of OMS-I100 in the treatment of metastatic melanoma. The results were presented by principal investigator Adil Daud, MD, at the Advances in Cancer Immunotherapy meeting at the University of California San Francisco.
OncoSec Medical Announces Hire of Chief Medical Officer
Business Wire - Thu Dec 12, 5:05AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, announced today that Dr. Robert H. Pierce has joined the company as Chief Medical Officer.
OncoSec Medical to Present at the 6th Annual LD Micro Conference
Business Wire - Tue Nov 26, 5:07AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, has announced it will be presenting at the Sixth Annual LD Micro Conference.
Exclusive Stock Reports on HIPP, QUAN and ONCS
ACCESSWIRE - Fri Nov 08, 12:32AM CST
Hipcricket Inc (OTC:HIPP), Quantum Internatinal Corp (OTC:QUAN) and OncoSec Medical Inc (OTC:ONCS) have been added to our watch list.
New In Depth Equity Reports on ONCS, DROP and MSLP
ACCESSWIRE - Mon Oct 28, 12:16AM CDT
OncoSec Medical Inc. (PINK: ONCS), Fuse Science, Inc. (OTC: DROP), and MusclePharm Corporation (OTC: MSLP) have been added to our watch list.
OncoSec President and CEO Publishes New Blog Entitled "PD-1 and OncoSec's Combination Study"
ACCESSWIRE - Mon Oct 21, 8:43AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), published a new blog post on The Chairman's Blog, written by the company's President and CEO, Punit Dhillon. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
OncoSec Medical Announces Positive Preliminary Safety Data in Combination Study
Business Wire - Tue Oct 08, 5:05AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, has announced positive preliminary animal data demonstrating the benefits of combining the company's ImmunoPulse with anti-CTLA4 and anti-PD1 antibodies.
OncoSec Medical to Present at the 2013 Aegis Capital Healthcare Conference
Business Wire - Fri Sep 20, 5:05AM CDT
OncoSec Medical Inc. (OTCQB:ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, has announced it will be presenting at the 2013 Aegis Capital Healthcare Conference. The presentation will take place at 9:45am PT on Thursday, September 26 at The Encore at Wynn in Las Vegas, NV.
OncoSec Medical Closes $12 Million Public Offering
Business Wire - Thu Sep 19, 5:05AM CDT
OncoSec Medical Inc. (OTCQB:ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, today announced that it has closed a registered public offering of 47,792,000 shares of its common stock at $0.25 per share and warrants to purchase up to 23,896,000 shares of common stock at an exercise price of $0.35 per share for four years.
OncoSec Medical Inc reports launch of USD12m public offering
M2 - Tue Sep 17, 6:58AM CDT
Biopharmaceutical company OncoSec Medical Inc (Other OTC:ONCS) announced on Monday the execution of definitive agreements to sell USD12m of securities in a registered public offering.
OncoSec Medical Announces $12 Million Public Offering
Business Wire - Mon Sep 16, 5:05AM CDT
OncoSec Medical Inc. (OTCQB:ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, announced today that it has entered into definitive agreements with institutional investors to purchase approximately $12 million of securities in a registered public offering. OncoSec has agreed to sell to institutional investors an aggregate of 47,792,000 shares of its common stock at $0.25 per share. Additionally, investors will receive warrants to purchase up to 23,896,000 shares of common stock at an exercise price of $0.35 per share for a term of four years.
(0)
(0)OncoSec Medical Incorporated (ONCS) Stock Research Links
Scroll down for more posts ▼